National Institute of Allergy & Infectious Diseases (NIAID)
31 Center Drive MSC 2520
Building 31, Room 7A-50
Bethesda
Maryland
20892-2520
United States
Tel: 301-496-5717
Website: http://www.niaid.nih.gov/
294 articles with National Institute of Allergy & Infectious Diseases (NIAID)
-
Heading into the Labor Day weekend in the U.S., there’s still plenty of COVID-19 news. Here’s a look.
-
Early data from a Phase III study for COVID-19 shows significant promise with its combo therapy reduced death and hospitalization in trial patients at high risk of progression by 78%.
-
President Biden is expected to be briefed on the lab leak theory conducted over the last 90 days. Very few expect solid results, although this might provide direction for more lines of inquiry.
-
Republican Senator Rand Paul is under fire from government watchdogs for failing to properly disclose a $15,000 purchase of Gilead Sciences stock made by his wife last year.
-
Rep. Michael McCaul issued a third installment today into the origins of the COVID-19 virus and blames the pandemic on a leak from the Wuhan Institute of Virology in China.
-
New data continues to emerge that seems to add to the possibility of COVID-19 originating from a lab leak at China’s Wuhan Institute of Virology.
-
Kytopen Awarded NIH Grant of Up to $2M to Unlock the Power of Engineered Natural Killer (NK) Cells via Flowfect® Platform
6/16/2021
NIH/NIAID SBIR Fast Track grant accelerates the company’s commercial activities towards a non-viral delivery platform that alleviates current limitations on NK cell gene editing
-
Fauci E-mails Raise Critical Questions, States the Association of American Physicians and Surgeons (AAPS)
6/3/2021
Controversy has erupted concerning the thousands of emails to and from Dr. Anthony Fauci that were released in response to Freedom of Information Act requests from Buzzfeed and the Washington Post.
-
Several biotech executives provided their thoughts on lessons learned from the pandemic and what they hope or expect to see moving forward in the industry.
-
When the pandemic hit, many companies diverted resources aimed at HIV to COVID-19, which ended up pausing some research efforts.
-
Spero Therapeutics Awarded up to $23 Million by the National Institute of Allergy and Infectious Diseases to Support the Development of SPR206
5/17/2021
The National Institute of Allergy and Infectious Diseases will fund the continued clinical development of product candidate SPR206
-
COVID-19 News: Researchers Discover a New Variant, Antiviral Shows Promise in Hamsters and More
4/20/2021
Please check out the biopharma industry's COVID-19 stories that are trending for April 20, 2021. -
Moderna Announces Shipment of 100 Millionth Dose of its COVID-19 Vaccine to the U.S. Government
3/29/2021
Moderna, Inc. announced that the Company has shipped the 100-millionth dose of its COVID-19 vaccine to the U.S. Government. More than 67 million doses of the Moderna COVID-19 Vaccine have been administered in the U.S., according to the U.S. Centers for Disease Control and Prevention.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 23, 2021.
-
Aridis Pharmaceuticals Provides Multiple Program Updates Including the Addition of a Second Inhaled Antibody to Neutralize Newly Emerging COVID-19 Mutated Variants
2/23/2021
National Institute of Allergy and Infectious Disease (NIAID) and the Coronavirus Immunotherapy Consortium (CoVIC) are providing preclinical services support to accelerate development
-
ATCC Announces Award of HIV Reagent Program
2/1/2021
ATCC joins National Institute of Allergy and Infectious Diseases' team working on preclinical services for HIV therapeutics
-
Celdara Medical and the University of Vermont Secure NIH Funding to Improve Pandemic Preparedness and Response
1/19/2021
Celdara Medical, LLC announced that the National Institute of Allergy and Infectious Disease of the National Institutes of Health has awarded it a two-year Small Business Technology Transfer Research grant to fund the development of a novel, broad-spectrum therapeutic/prophylactic against RNA viruses, including SARS-CoV-2, SARS, Ebola, influenza, and pathogenic arenaviruses.
-
Gritstone Advances Second Generation COVID-19 Vaccine “CORAL” Program with Support from NIAID; Program has Potential to Protect Against Mutant Variants of SARS-CoV-2
1/19/2021
Gritstone Oncology, Inc., a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, announced that it is advancing development of a second generation vaccine against SARS-CoV-2, the virus that causes COVID-19, with potential for both prolonged protection and potency against Spike mutants.
-
Jaguar Health Subsidiary Receiving Preclinical Services from the NIAID for New Preclinical Study Initiated January 6, 2021 for Lechlemer Plant-Based Drug Candidate for the Symptomatic Relief of Diarrhea from Cholera
1/6/2021
Jaguar Health, Inc. announced that the 28-day preclinical toxicology and safety study in dogs began today, January 6, 2021, to support development of lechlemer, the second generation, plant-based anti-secretory drug candidate of Napo Pharmaceuticals, Jaguar's wholly owned subsidiary, for the symptomatic relief of diarrhea from cholera.
-
Dr. Anthony Fauci to Speak at University of Chicago on March 4
12/21/2020
Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health will join the University of Chicago Harris School of Public Policy on March 4 for a conversation hosted by its dean, Katherine Baicker, who will award Dr. Fauci the 2020 Harris Dean's Award.